Comparative Pharmacology
Head-to-head clinical analysis: ECOZA versus EXSEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECOZA versus EXSEL.
ECOZA vs EXSEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
1-2 mg orally once daily; maximum dose 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Category C
Category C
Topical Antifungal
Topical Antifungal